Clinical trials: Anthracyclines
Advanced Soft Tissue Sarcoma
Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)
Maintenance Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)
- Trial name
- MELODY (NCT06981637)
- Testing
- Pegylated liposomal doxorubicin
- Where
- 7 sites in Taiwan
- Volunteers
- 81 people
- Sponsor
- National Health Research Institutes, Taiwan
Breast Cancer
Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity
The purpose of this study is to evaluate whether dapagliflozin reduces chemotherapy-induced cardiotoxicity in participants with breast cancer treated with (neo-)adjuvant Anthracycline-based chemotherapy +/- trastuzumab.
- Trial name
- PROTECT (NCT06341842)
- Testing
- Dapagliflozin 10mg Tab
- Where
- Italy
- Volunteers
- 316 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Breast Cancer
Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years
This is a multicenter study of a primary chemotherapy regimen in breast cancer patients at risk of developing cardiotoxicity. The aim of the study is to evaluate the response rate at surgery.
- Trial name
- CAPRICE (NCT00563953)
- Testing
- Liposomal pegylated doxorubicine
- Where
- 8 sites in Spain
- Volunteers
- 50 people
- Sponsor
- SOLTI Breast Cancer Research Group
Extravasation
A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines
The purpose of this study is To prevent progression of a lesion caused by anthracycline extravasation into necrosis, which would require surgical intervention To prevent development of deep tissue necrosis and destruction leading…
- Trial name
- NCT00548704
- Testing
- Dexrazoxane
- Where
- 34 sites in Denmark, Germany and 3 more
- Volunteers
- 57 people
- Sponsor
- Valerio Therapeutics
Breast Cancer, Lymphoma, Large B-Cell, Diffuse
Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines
As the cancer-related prognosis improves thanks to recent advances in cancer-targeted therapies, the prognostic burden of chemotherapy-related complications - including cardiotoxicity - is increasingly recognised.
- Conditions
- Breast Cancer, Lymphoma, Large B-Cell, Diffuse, Cardiotoxicity, Left Ventricular Dysfunction
- Trial name
- CONTROL (NCT05728632)
- Testing
- Nebivolol
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Giulio Stefanini
Metastatic Breast Cancer
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
The purpose is to investigate anti-tumor effect of ixabepilone in patients with locally recurrent or metastatic breast cancer (mBC) selected by the Ixabepilone DRP after failure of an anthracycline and taxanes.
- Trial name
- NCT04796324
- Testing
- Ixabepilone Injection
- Where
- 19 sites in Belgium, Finland and 5 more
- Volunteers
- 13 people
- Sponsor
- Allarity Therapeutics
Sarcoma
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
The primary objective of the study is to compare the progression-free survival (PFS) in the 2 treatment arms The secondary objectives of the study are : To compare the overall survival in the 2 treatment arms To compare the…
- Trial name
- NCT00699517
- Testing
- OMBRABULIN (AVE8062)
- Where
- 45 sites in United States, Belgium and 8 more
- Volunteers
- 355 people
- Sponsor
- Sanofi
Breast Neoplasms, Adjuvant
Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer
Anthracycline based regimens followed by a taxane (CALGB-9344 trial and NSABP-B28) or reversed (MD Anderson Adjuvant Trial) has already accepted as adjuvant therapy for node positive breast cancer.
- Conditions
- Breast Neoplasms, Adjuvant, Chemotherapy
- Trial name
- NCT00525642
- Testing
- Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide
- Where
- 5 sites in China
- Volunteers
- 603 people
- Sponsor
- Fudan University
Breast Cancer
Cardiotoxicity of Cancer Therapy (CCT)
The objective of this study is to define the clinical significance of mechanistic biomarkers (including Neuregulin-1Beta) and novel echocardiographic measures of cardiac function in predicting the incident risk of cancer therapy…
- Trial name
- NCT01173341
- Testing
- Echocardiography, Blood Collection, Symptoms Questionnaire
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Heart Injuries, Anthracycline
Cardiac Injury Due to Anthracycline in Paediatric Oncological Patients
The study investigates the role of echocardiography and of serum biomarkers (NT-proBNP, cardiac Troponin-I) in predicting cardiac injury in a cohort of paediatric oncological patients treated with Anthracycline chemotherapy.
- Trial name
- NCT06898320
- Where
- Italy
- Volunteers
- 22 people
- Sponsor
- IRCCS Burlo Garofolo
Breast Cancer Female
Caloric Restriction and Exercise for Protection From Anthracycline Toxic Effects
Doxorubicin and epirubicin are part of the class of chemotherapy agents called anthracyclines that are commonly used to treat breast cancer.
- Trial name
- CREATE (NCT03131024)
- Testing
- 50% caloric restriction, Aerobic exercise
- Where
- Canada
- Volunteers
- 58 people
- Sponsor
- University of Alberta
Breast Cancer
A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine
The purpose of this study is to evaluate the efficacy and safety of E7389 in Patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine as prior therapy, and who…
- Trial name
- NCT00246090
- Testing
- E7389
- Where
- 65 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- Eisai Inc.
Breast Cancer
Maintenance Chemotherapy in Metastatic Breast Cancer
This is a randomized, prospective and multicenter phase III study. Two-hundred-sixty-two (262) patients on each arm will be recruited in the study.
- Trial name
- NCT00289263
- Testing
- Paclitaxel
- Where
- 7 sites in Italy
- Volunteers
- 524 people
- Sponsor
- MANTA 1 Study Italian Collaborative Group
Breast Cancer, Triple Negative Breast Cancer
Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer
This phase II randomized trial is for patients with clinical stage II-III, ER and PR <10%, HER2-negative invasive breast carcinoma (triple negative breast cancer) for whom adjuvant RT is planned and pre-operative RT is deemed…
- Trial name
- PANDoRA (NCT03872505)
- Testing
- Durvalumab, Radiation Therapy, Carboplatin
- Where
- United States
- Sponsor
- Cedars-Sinai Medical Center
Estrogen Receptor Negative, Estrogen Receptor Positive
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
This phase II trial studies how well pembrolizumab and doxorubicin hydrochloride works compared to pembrolizumab with anti-estrogen therapy (anastrozole, letrozole, or exemestane) in treating patients with triple-negative or…
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative
- Trial name
- NCT02648477
- Testing
- Anastrozole, Doxorubicin Hydrochloride, Exemestane
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
This multicenter, non-randomized, open-label, phase 2 study is designed to evaluate the safety and efficacy of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and anthracycline-based chemotherapy as neoadjuvant…
- Trial name
- BERENICE (NCT02132949)
- Testing
- 5-Fluorouracil, Cyclophosphamide, Docetaxel
- Where
- 80 sites in United States, Canada and 10 more
- Volunteers
- 401 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer
This single-arm open-label study assessed the safety, feasibility, and efficacy of trastuzumab emtansine (T-DM1) after the completion of anthracycline-based adjuvant/neoadjuvant chemotherapy in patients with early HER2-positive…
- Trial name
- NCT01196052
- Testing
- Trastuzumab emtansine
- Where
- 44 sites in United States, Belgium and 6 more
- Volunteers
- 153 people
- Sponsor
- Hoffmann-La Roche
Cardiotoxicity, Cardiac Rehabilitation
Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity
This project aims to determine whether a comprehensive cardiac rehabilitation program including supervised exercise training is able to prevent cardiotoxicity during treatment with anthracyclines and / or anti-HER-2 antibodies in…
- Trial name
- ONCORE (NCT03964142)
- Testing
- Cardiac rehabilitation
- Where
- Spain
- Volunteers
- 122 people
- Sponsor
- Hospital Clinico Universitario de Santiago
Advanced Solid Tumours
Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours
This is a single-centre, open label, dose finding, phase I study to determine the recommended phase II dose (RP2D) for the combination of doxorubicin and pantoprazole in patients with advanced tumours and no standard treatment…
- Trial name
- NCT01163903
- Testing
- pantoprazole sodium for injection, doxorubicin hydrochloride injection
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- University Health Network, Toronto
Sarcoma
PCI-24781 in Combination With Doxorubicin to Treat Sarcoma
The purpose of this research study is to determine the safety and maximum tolerated dose of PCI-24781 that can be given safely with doxorubicin (phase I) and the safety and efficacy of PCI-24781 when used in combination with…
- Trial name
- NCT01027910
- Testing
- PCI-24781, Doxorubicin, GCSF
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital